GM knew about this problem in 2001. They were warned again and again over the next decade, but they did nothing.
Diana DeGette
The Public Record
Diana Louise DeGette is a U.S. Representative for Colorado's 1st congressional district, having served since January 3, 1997. A member of the Democratic Party, she has been a prominent advocate for health care reform and women's rights throughout her tenure in Congress. DeGette has played a significant role in various legislative efforts, particularly in expanding access to health care services. Her work has garnered support from organizations such as the National Association of Community Health Centers.
In February of 2002, GM's ignition switch supplier, Delphi, informed the company that the switch did not meet GM's minimum specifications, but GM approved it anyway.
Like all of us, I am deeply troubled about what our investigation has revealed about GM's business practices and its commitment to safety.
We are going to get to the bottom of this. We are going to figure out what happened, and we are going to make sure it doesn't happen again.
We know that GM has recalled over 2.5 million vehicles because of defective ignition switches.
I hope that we can address them today, and also as we continue our joint efforts to work towards comprehensive mental health legislation.
If you did have this investment of resources and you were really able to implement things like this, it would actually probably save money.
I think this sets a record as the biggest panel we have ever had in this subcommittee.
One reason why this problem is getting worse is because of budget cuts for mental health and addiction services.
It is designed to get treatment to folks earlier on without having them participate in the penal system.
you don't know this, Sheriff, but I started my career as a public defender, and so I know this very, very well.
Yes, and I want to ask you, Ms. Ashley, as a fellow mom here, you would much rather--you, as a nurse, identified that your son had severe psychiatric problems from an early stage but you didn't have any recourse to get him the kind of…
The question for this hearing, where have all the patients gone, is a very important one.
I have been on this subcommittee for 18 years, and this is, I think, maybe the best panel we have ever had.
If enacted, this proposal would weaken current law and endanger public health. That is why I cannot support the bill in its current form.
I know House Democrats can pass a TSCA bill without Republican support. But I also believe, Mr. Chairman, that House Republicans cannot enact a law without the support of House Democrats.
I just want to reiterate that I am pleased that we are continuing to have conversations, and there is some progress that is made in this draft bill.
I hope we pay close attention to the testimony today and then renew our efforts to find common ground.
I am the co-chair of the Diabetes Caucus, so I was horrified to hear your insulin example.
Counterfeit drugs can contain dangerous impurities, incorrect ingredients, improper dosages, and also have improper handling.
I think the sentences need to be increased, but I am trying to figure out, and this is what I was talking to the chairman about, is how much is increasing sentences really going to prevent this kind of conduct.
Do you think the problem of counterfeit drugs has gotten worse in recent years?
They are going to be more sophisticated on that end, and we have got to be more sophisticated.
Thank you very much, Mr. Chairman. And if you can help convey with me to Mr. Murphy that we should continue this oversight, I think that would be great.





